Renal Function Impairment in Peripheral Arterial Disease: An Important Parameter that Should not Be Neglected

Annals of Vascular Surgery

Volumn 23, Issue 5, 2009, Pages 690-699

  Paraskevas, Kosmas I ^a   Giannoukas, Athanassios D ^b   Mikhailidis, Dimitri P ^c  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; GRAFT PATENCY; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LEG REVASCULARIZATION; LIMB SALVAGE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CREATININE; EVIDENCE-BASED MEDICINE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY DISEASES; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 69849097332     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2009.06.002     Document Type: Review

References (87)

1. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110 (2004) 738-743
2. Pfeiffer M., Bock E., Hohenberger T., et al. The Arteriomobil Project for peripheral arterial disease. Vasa 37 (2008) 345-352
3. Khan S., Flather M., Mister R., et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur. J. Vasc. Endovasc. Surg 33 (2007) 442-450
4. Dormandy J., Heeck L., and Vig S. The natural history of claudication: risk to life and limb. Semin. Vasc. Surg 12 (1999) 123-137
5. Dormandy J., Heeck L., and Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin. Vasc. Surg 12 (1999) 118-122
6. Coppola G., and Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch. Med. Res. 38 (2007) 479-488
7. Poredos P., and Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 58 (2007) 309-315
8. Von Kemp K., van den Brande P., Peterson T., et al. Screening for concomitant diseases in peripheral vascular patients. Results of a systematic approach. Int. Angiol 16 (1997) 114-122
9. Feringa H.H., Karagiannis S.E., Chonchol M., et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J. Am. Soc. Nephrol 18 (2007) 1872-1879
10. Pasqualini L., Schillaci G., Pirro M., et al. Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. J. Intern. Med 262 (2007) 668-677
11. Safian R.D., and Textor S.C. Renal-artery stenosis. N. Engl. J. Med 344 (2001) 431-442
12. Meier P., Rossert J., Plouin P.F., et al. Atherosclerotic renovascular disease: beyond the renal artery stenosis. Nephrol. Dial. Transplant 22 (2007) 1002-1006
13. Choudhri A.H., Cleland J.G., Rowlands P.C., et al. Unsuspected renal artery stenosis in peripheral vascular disease. B.M.J 301 (1990) 1197-1198
14. Wachtell K., Ibsen H., Olsen M.H., et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J. Hum. Hypertens 10 (1996) 83-85
15. Leertouwer T.C., Pattynama P.M., and van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment?. Kidney Int 59 (2001) 1480-1483
16. Mui K.W., Sleeswijk M., van den Hout H., et al. Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J. Am. Soc. Nephrol 17 (2006) 2069-2074
17. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003) 225-232
18. Blickle J.F., Doucet J., Krummel T., et al. Diabetic nephropathy in the elderly. Diabetes Metab 33 (2007) S40-S55
19. Schutta M.H. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr 2 (2007) 124-130
20. Garovic V.D., and Textor S.C. Renovascular hypertension and ischemic nephropathy. Circulation 112 (2005) 1362-1374
21. Baggio B., Budakovic A., Casara D., et al. Renal involvement in subjects with peripheral atherosclerosis. J. Nephrol 14 (2001) 286-292
22. Pillay W.R., Kan Y.M., Crinnion J.N., et al. Joint Vascular Research Group, UK. Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br. J. Surg 89 (2002) 737-740
23. Langlois M., De Bacquer D., Duprez D., et al. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis 168 (2003) 163-168
24. Kshirsagar A.V., Coresh J., Brancati F., et al. Ankle brachial index independently predicts early kidney disease. Ren. Fail 26 (2004) 433-443
25. O'Hare A.M., Rodriguez R.A., and Bacchetti P. Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch. Intern. Med 165 (2005) 1481-1485
26. Rashid S.T., Salman M., Agarwal S., et al. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine. Eur. J. Vasc. Endovasc. Surg 32 (2006) 294-299
27. Mlekusch W., Exner M., Sabeti S., et al. Serum creatinine predicts mortality in patients with peripheral artery disease: influence of diabetes and hypertension. Atherosclerosis 175 (2004) 361-367
28. O'Hare A.M., Bertenthal D., Shlipak M.G., et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J. Am. Soc. Nephrol 16 (2005) 514-519
29. Goessens B.M., van der G.Y., Olijhoek J.K., et al., SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J. Vasc. Surg 45 (2007) 47-54
30. O'Hare A.M., Feinglass J., Sidawy A.N., et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the Department of Veterans Affairs' National Surgical Quality Improvement Program. J. Am. Soc. Nephrol 14 (2003) 1287-1295
31. O'Hare A.M., Sidawy A.N., Feinglass J., et al. Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization. J. Vasc. Surg 39 (2004) 709-716
32. Owens C.D., Ho K.J., Kim S., et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J. Vasc. Surg 45 (2007) 944-952
33. Maithel S.K., Pomposelli F.B., Williams M., et al. Creatinine clearance but not serum creatinine alone predicts long-term postoperative survival after lower extremity revascularization. Am. J. Nephrol 26 (2006) 612-620
34. Fabsitz R.R., Sidawy A.N., Go O., et al. Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. Am. J. Epidemiol 149 (1999) 330-338
35. Newman A.B., Siscovick D.S., Manolio T.A., et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. Circulation 88 (1993) 837-845
36. Zheng Z.J., Sharrett A.R., Chambless L.E., et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131 (1997) 115-125
37. Murabito J.M., Evans J.C., Larson M.G., et al. Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch. Intern. Med 163 (2003) 1939-1942
38. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler. Thromb. Vasc. Biol 19 (1999) 538-545
39. Leng G.C., Fowkes F.G., Lee A.J., et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. B.M.J 313 (1996) 1440-1444
40. Tsai A.W., Folsom A.R., Rosamond W.D., et al. Ankle-brachial index and 7-year ischemic stroke incidence: the ARIC study. Stroke 32 (2001) 1721-1724
41. Marso S.P., and Hiatt W.R. Peripheral arterial disease in patients with diabetes. J. Am. Coll. Cardiol 47 (2006) 921-929
42. Weiss J.S., and Sumpio B.E. Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur. J. Vasc. Endovasc. Surg 31 (2006) 143-150
43. Al-Aly Z. Medial vascular calcification in diabetes mellitus and chronic kidney disease: the role of inflammation. Cardiovasc. Hematol. Disord. Drug Targets 7 (2007) 1-6
44. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr. Diab. Rep 6 (2006) 479-483
45. Clement D.L., De Buyzere M.L., and Duprez D.A. Hypertension in peripheral arterial disease. Curr. Pharm. Des 10 (2004) 3615-3620
46. Olin J.W. Hypertension and peripheral arterial disease. Vasc. Med 10 (2005) 241-246
47. Kerut E.K., Geraci S.A., Falterman C., et al. Atherosclerotic renal artery stenosis and renovascular hypertension: clinical diagnosis and indications for revascularization. J. Clin. Hypertens. (Greenwich) 8 (2006) 502-509
48. Alnaeb M.E., Alobaid N., Seifalian A.M., et al. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann. Vasc. Surg 20 (2006) 696-705
49. Daskalopoulou S.S., Daskalopoulos M.E., Mikhailidis D.P., et al. Lipid management and peripheral arterial disease. Curr. Drug Targets 8 (2007) 561-570
50. Youssef F., Gupta P., Seifalian A.M., et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55 (2004) 53-62
51. Daskalopoulou S.S., Daskalopoulos M.E., Liapis C.D., et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr. Med. Chem 12 (2005) 443-452
52. Paraskevas K.I., Hamilton G., Mikhailidis D.P., et al. Optimal medical management of peripheral arterial disease. Vasc. Endovascular Surg 41 (2007) 87
53. Alnaeb M.E., Youssef F., Mikhailidis D.P., et al. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 57 (2006) 65-71
54. Daskalopoulou S.S., Athyros V.G., Hamilton G., et al. Lipid-lowering therapy in patients with peripheral arterial disease. J. Cardiovasc. Pharmacol. Ther 10 (2005) 145-147
55. Davis M., Atwal A.S., Nair D.R., et al. The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr. Med. Res. Opin 16 (2000) 198-204
56. Elisaf M., and Mikhailidis D.P. Statins and renal function. Angiology 53 (2002) 493-502
57. Feringa H.H., Karagiannis S.E., van Waning V.H., et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J. Vasc. Surg 45 (2007) 936-943
58. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg 45 (2007) 645-654
59. Paraskevas K.I., Bessias N., Tzorbatzoglou J., et al. Effect of statins on renal function in patients with peripheral arterial disease. Vasc. Endovascular Surg 42 (2008) 620-621
60. Paraskevas K.I., Liapis C.D., Hamilton G., et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur. J. Vasc. Endovasc. Surg 32 (2006) 286-293
61. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-e654
62. Poussa H., Strandberg T.E., Tikkanen I., et al. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Scand. Cardiovasc. J 41 (2007) 138-141
63. Hirsch A.T., and Gotto Jr. A.M. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc. Med 7 (2002) 323-331
64. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J.A.M.A 286 (2001) 1317-1324
65. Youssef F., Gupta P., Mikhailidis D.P., et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 56 (2005) 279-287
66. Burns P., Gough S., and Bradbury A.W. Management of peripheral arterial disease in primary care. B.M.J 326 (2003) 584-588
67. Rehring T.F., Sanhoff B.G., Stolcpart R.S., et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J. Vasc. Surg 41 (2005) 816-822
68. Mann J.F., Gerstein H.C., Pogue J., et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med 134 (2001) 629-636
69. Bosch J., Lonn E., Pogue J., et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112 (2005) 1339-1346
70. Mann J.F., Gerstein H.C., Yi Q.L., et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J. Am. Soc. Nephrol 14 (2003) 641-647
71. McDermott M.M., Mandapat A.L., Moates A., et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch. Intern. Med 163 (2003) 2157-2162
72. McDermott M.M., Hahn E.A., Greenland P., et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J. Gen. Intern. Med 17 (2002) 895-904
73. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. J.A.M.A 295 (2006) 547-553
74. Duprez D.A. Pharmacological interventions for peripheral artery disease. Expert Opin. Pharmacother 8 (2007) 1465-1477
75. Benko A., Fraser-Hill M., Magner P., et al. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can. Assoc. Radiol 58 (2007) 79-87
76. Schweiger M.J., Chambers D.E., Davidson C.J., et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter. Cardiovasc. Interv 69 (2007) 135-140
77. Lameier N.H. Contrast-induced nephropathy-prevention and risk reduction. Nephrol. Dial. Transplant 21 (2006) i11-i23
78. Bianchi C., Montalvo V., Ou H.W., et al. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann. Vasc. Surg 21 (2007) 163-166
79. Brevetti G., Oliva G., Giugliano G., et al. Mortality in peripheral arterial disease: a comparison of patients managed by vascular specialists and general practitioners. J. Gen. Intern. Med 22 (2007) 639-644
80. Randers E., Kristensen J.H., Erlandsen E.J., et al. Serum cystatin C as a marker of the renal function. Scand. J. Clin. Lab. Invest 58 (1998) 585-592
81. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am.. J. Kidney Dis 37 (2001) 79-83
82. Keller T., Messow C.M., Lubos E., et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur. Heart J 30 (2009) 312-320
83. Song S., Meyer M., Turk T.R., et al. Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. Nephrol. Dial. Transplant 24 (2009) 1157-1161
84. Seronie-Vivien S., Delanaye P., Pieroni L., et al. Cystatin C: current position and future prospects. Clin. Chem. Lab. Med 46 (2008) 1664-1686
85. Beringer P.M., Hidayat L., Heed A., et al. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J. Cyst. Fibros 8 (2009) 19-25
86. Muntner P., Mann D., Winston J., et al. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am. J. Cardiol 102 (2008) 54-57
87. Arpegard J., Ostergren J., de Faire U., et al. Cystatin C-a marker of peripheral atherosclerotic disease?. Atherosclerosis 199 (2008) 397-401